Antiphospholipid antibodies and osteonecrosis in systemic lupus erythematosus: a meta-analysis. (3rd August 2021)

• Record Type: Journal Article
• Authors: Qijiao, Wei; Meng, Zhou; Jianwen, Liu; Shengli, Zhang; Fei, Gao; He, Lin; Zhihan, Chen
• Is Part Of: Expert review of clinical immunology. Volume 17:Number 8(2021)
• Page Start: 923
• Page End: 932
• Publication Date: 2021-08-03
• Subjects: Antiphospholipid antibody -- antiphospholipid antibody syndrome -- meta-analysis -- osteonecrosis -- systemic lupus erythematosus; Clinical immunology -- Periodicals; 616.079
• DOI: 10.1080/1744666X.2021.1925109
• Languages: English
• ISSNs: 1744-666X

Abstract

ABSTRACT: Objectives : The present meta-analysis aimed to assess the relationship between antiphospholipid antibodies (aPLs) or antiphospholipid antibody syndrome (APS) and the incidence of osteonecrosis (ON) in systemic lupus erythematosus (SLE) patients. Methods : MEDLINE/Pubmed, EMBASE, Web of science, the Chinese Biomedical Literature Database (CBM), the Wan-Fang Database, and the China National Knowledge Infrastructure (CNKI) were searched from their inception up until 26 December 2020. Studies in English were included. Case–control studies and cohort studies were included. Studies pertaining to the link between aPLs or APS and ON patients were slated for inclusion in the current analysis. Results : Twenty-two studies involving a total of 3054 SLE patients were included. The positivities of anticardiolipin antibody (ACL), IgG ACL, IgM ACL, LA and APS in SLE is not associated with ON. One study showed that IgG or IgM β2GP1 had no association with ON. No publication bias was detected. The quality of this evidence was low because of the high risk of bias across studies, and therefore robust inferences cannot be made. Conclusion : SLE patients demonstrated a weak association between aPLs and ON. The nature of the association between aPLs and ON in SLE needs to be investigated in-depth in future research.